CG Oncology, Inc.
About CG Oncology, Inc.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.0M
- Total assets
- $791.6M
- Market cap
- $4.7B
- Operating margin
- -4722.1%
- Net margin
- -3985.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.0M
- Operating expenses
- $194.8M
- Operating income
- -$190.8M
- Income tax
- -$270.0K
- Net income
- -$161.0M
- EPS (basic)
- $-2.08
- EPS (diluted)
- $-2.08
Balance sheet
- Total assets
- $791.6M
- Current assets
- $759.5M
- Total liabilities
- $39.0M
- Current liabilities
- $30.8M
- Shareholders’ equity
- $752.6M
Cash flow
- Operating cash flow
- -$132.3M
- Investing cash flow
- -$245.8M
- Financing cash flow
- $153.6M
- Net cash flow
- -$224.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.7B
- EPS (diluted)
- $-2.08
- Shares outstanding
- 87.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $161.0M.
- Revenue grew 255% from FY2024 to FY2025.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CG Oncology, Inc..
Write a review
News about CG Oncology, Inc.
News & sentiment via Polygon.io
